Skip to content
Clinical Trials
Our Network
Our Story
Clinical Trials
Our Network
Our Story
OnCore Login
Clinical Trials
Current Trials
Publications
Our Network
Clinical Trial Working Groups
Sponsor-Investigators
Fostering an Environment of Mentorship
Member Sites
Partners in Research
About
Our Story
Our Team
Annual Reports
Services
Biorepository & Correlative Services
Rapid Accrual
Efficient Timelines for Activation
Regulatory Compliance
Accurate & Relevant Data
News & Events
HCRN Calendar
Oncology Meetings
Make a Difference
Donate Now
Fundraising Events
Advocacy Organizations
Honor Your Hero
Careers
Contact
OnCore Login
A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with BRCA1/2 gene alterations (NePtune)
Current Trials
Our Network
Our Story
X